Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Cash from Operations (2023 - 2025)

Kura Oncology (KURA) has disclosed Cash from Operations for 3 consecutive years, with 117273000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 56.43% to 117273000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 64058000.0 through Dec 2025, down 147.69% year-over-year, with the annual reading at 64058000.0 for FY2025, 147.69% down from the prior year.
  • Cash from Operations for Q4 2025 was 117273000.0 at Kura Oncology, up from 80627000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 269131000.0 in Q4 2024, with the low at 80627000.0 in Q3 2025.
  • Average Cash from Operations over 3 years is 4547083.33, with a median of 35090000.0 recorded in 2023.
  • The sharpest move saw Cash from Operations surged 884.46% in 2024, then plummeted 85.61% in 2025.
  • Over 3 years, Cash from Operations stood at 34308000.0 in 2023, then soared by 884.46% to 269131000.0 in 2024, then tumbled by 56.43% to 117273000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 117273000.0, 80627000.0, and 28777000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.